A multicentric, hospital survey to evaluate the possible adverse drug reactions associated with thyroid medication

Vinod Hiraman Jadhav *, Rutuja Prafulla Deshpande, Ankita Devendra Vaidya, Jagruti Rajesh Patil and Divya Sangitrao Amzare

Department of pharmacology, Dr. Rajendra Gode Institute of Pharmacy, Amravati, Maharashtra, India.
 
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 27(03), 171–177.
Article DOI: 10.30574/gscbps.2024.27.3.0236
Publication history: 
Received on 07 May 2024; revised on 18 June 2024; accepted on 20 June 2024
 
Abstract: 
This study was conducted to identify and report the Adverse drug reactions (ADRs) associated with use of thyroid medications drugs pediatric and medicine Departments in a Tertiary Care hospital of Vidarbha Maharashtra. A multicentric hospital study was conducted for 4 months in-patient at a tertiary care teaching hospital. We enrolled the patients based on Inclusion criteria and data was analyzed with the help of MS excel 7 and Graph pad Prism. Further, the assessments of type, severity, and preventability of reported ADRs were done using Wills and Brown classification, modified Schumock and Thornton severity scale, modified Hartwig and Siegel Preventability scale. Data were collected from a total of 50 (100%) patients of which 19 (38%) patients were affected with ADRs. Among twelve Patients, females (24%) were more affected with ADRs when compared to males (14%).  Based on the type of ADRs, Type D ADRs (58%) were more observed followed by Type A (23%) and Type B (5%). We reported more prevalence of female patients experiencing ADRs associated with use of antithyroid drugs as compared to Male patients.
 
Keywords: 
Hypothyrodism; Thyroid medication; ADRs; Wills and Brown classification scale; Modified Schumock and Thornton severity scale; Modified Hartwig and Siegel Preventability scale.
 
Full text article in PDF: 
Share this